Ulinastatin: Is it worth using in severe sepsis?

Intensive Care Medicine

Volumn 40, Issue 8, 2014, Pages 1185-

  Saigal, Saurabh ^a   Kapoor, Garima ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b GANDHI MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; COLISTIN; NETILMICIN; PLACEBO; ULINASTATIN; ANTIBIOTIC AGENT; GLYCOPROTEIN; TRYPSIN INHIBITOR;

HUMAN; LETTER; SEPSIS; SEPTIC SHOCK; ANTIBIOTIC THERAPY; APACHE; DISEASE ASSOCIATION; HEALTH CARE COST; INTENSIVE CARE UNIT; MORTALITY; PATIENT ADVOCACY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; FEMALE; MALE;

FEMALE; GLYCOPROTEINS; HUMANS; MALE; SEPSIS; TRYPSIN INHIBITORS;

EID: 84904857843     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3341-5     Document Type: Letter

References (5)

1. Antonelli M, Bonten M, Chastre J et al (2012) Year in review in intensive care medicine 2011: I. nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimental. Intensive Care Med 38:192-209
2. Karnad DR, Bhadade R, Verma PK et al (2014) Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. doi:10.1007/s00134-014-3278-8
3. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165-228
4. Yealy DM, Kellum JA, Huang DT, The Process Investigators et al (2014) A randomized trial of protocol based care for early septic shock. N Engl J Med 370(18):1683-1693
5. Caironi P, Tognoni G, Masson S et al (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370(15):1412-1421